SCHEMBL4469178

SCHEMBL4469178

NC(=O)Nc1cccc(N(c2ccc(F)cc2)C(c2cccnc2)c2cccnc2)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.41
KCNA5 P22460 2/20 0.39
KCNE1 P15382 1/20 0.39
KCNQ1 P51787 1/20 0.39
KCND3 Q9UK17 1/20 0.39
LMNA P02545 2/20 0.38
CYP11B1 P15538 1/20 0.37
CYP11B2 P19099 1/20 0.37
SCN9A Q15858 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
MAPT P10636 2/20 0.35
TP53 P04637 1/20 0.35
NR3C2 P08235 1/20 0.34
EPHX2 P34913 1/20 0.34
ATR Q13535 1/20 0.34
THRB P10828 1/20 0.34
TAAR1 Q96RJ0 1/20 0.34
KDM4E B2RXH2 1/20 0.34
CDK5 Q00535 1/20 0.34
CDK5R1 Q15078 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4456765 0.90 POLB (0.42) POLBKCNA5KCNE1KCNQ1KCND3
SCHEMBL4453045 0.90 NR3C2 (0.39) NR3C2EPHX2KDM4E
SCHEMBL4458292 0.88 POLB (0.42) POLBKCNA5KCNE1KCNQ1KCND3
SCHEMBL4462113 0.83 ALDH1A1 (0.40) POLBNR3C2
SCHEMBL14435382 0.83 KCNA5 (0.39) POLBKCNA5KCNE1KCNQ1KCND3
SCHEMBL4461864 0.81 SMN1; SMN2 (0.38) KCNA5LMNAL3MBTL1EPHX2
SCHEMBL4457249 0.81 KCNA5 (0.61) POLBKCNA5KCNE1KCNQ1KCND3
SCHEMBL4470641 0.79 POLB (0.37) POLBKCNA5KCNE1KCNQ1KCND3
SCHEMBL4458360 0.79 POLB (0.37) POLBKCNA5KCNE1KCNQ1KCND3
SCHEMBL13971462 0.79 KCNA5 (0.38) POLBKCNA5KCNE1KCNQ1KCND3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090030043-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME CORP. 2009-01-29 US claimed
EP-1981507-A2 POTASSIUM CHANNEL INHIBITORS Merck & Co., Inc. (US) 2008-10-22 EP claimed
WO-2007089679-A2 POTASSIUM CHANNEL INHIBITORS MERCK & CO., INC. (US) 2007-08-09 WO claimed
US-20090030043-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME CORP. 2009-01-29 US disclosed
EP-1981507-A2 POTASSIUM CHANNEL INHIBITORS Merck & Co., Inc. (US) 2008-10-22 EP disclosed
WO-2007089679-A2 POTASSIUM CHANNEL INHIBITORS MERCK & CO., INC. (US) 2007-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030043-A1 Potassium Channel Inhibitors KCNJ2, KCNH2, KCNH3 POLB 4703/4885KCNA5 11/4885KCNE1 23/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.